ACE and non-Hodgkin lymphoma: When excluding 257 patients treated with ACE inhibitors from the analysis, sarcoidosis, non-Hodgkin’s lymphoma, cirrhosis, and interstitial lung disease still significantly increased the risk of elevated ACE levels.